Treatment of hepatitis C in potential kidney and heart transplant patients

Clinics in Liver Disease

Volumn 9, Issue 3, 2005, Pages 487-503

  Fabrizi, Fabrizio ^a,b   Bunnapradist, Suphamai ^c   Martin, Paul ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN3 INTERFERON; ANTIMETABOLITE; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; ERYTHROPOIETIN; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ANEMIA; BONE MARROW SUPPRESSION; CHILL; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIALYSIS; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GLOMERULONEPHRITIS; GRAFT DYSFUNCTION; HEART TRANSPLANTATION; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVER BIOPSY; META ANALYSIS; MYALGIA; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; SURVIVAL; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; RIBAVIRIN;

EID: 22044435954     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2005.05.006     Document Type: Review

References (100)

1. J.A. Fishman, R.H. Rubin, and M.J. Koziel Hepatitis C virus and organ transplantation Transplantation 62 1996 147 154
2. B.J. Pereira, E.L. Milford, and R.L. Kirkman Transmission of hepatitis C virus by organ transplantation N Engl J Med 325 1991 454 459
3. T.G. Wreghitt, J.J. Gray, and J.P. Allain Transmission of hepatitis C virus by organ transplantation in the United Kingdom J Hepatol 20 1994 768 772
4. F. Fabrizi, F.F. Poordad, and P. Martin Hepatitis C infection and the patient with end-stage renal disease Hepatology 36 2002 3 10
5. F. Fabrizi, P. Martin, and G. Lunghi Nosocomial transmission of hepatitis C virus infection in hemodialysis patients: clinical perspectives Int J Artif Organs 23 2000 805 816
6. J.I. Tokars, L. Finelli, and M.J. Alter National surveillance of dialysis-associated diseases in the United States, 2001 Semin Dial 17 2004 310 319
7. R.B. Fissell, J.L. Bragg-Gresham, and J.D. Woods Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOOPS Kidney Int 65 2004 2335 2342
8. M. Jadoul, J.L. Poignet, C. Geddes and HCV Collaborative Group The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European Multicentre Study Nephrol Dial Transplant 19 2004 904 909
9. P.M. Schneeberger, I. Keur, and A.M. van Loon The prevalence and incidence of hepatitis C virus infection among dialysis patients in the Netherlands: a nationwide prospective study J Infect Dis 182 2000 1291 1299
10. G. Salama, L. Rostaing, and K. Sandres Hepatitis C virus infection in French hemodialysis units: a multicenter study J Med Virol 61 2000 44 51
11. A. Kashem, I. Nusairat, and M. Mohamad Hepatitis C virus among hemodialysis patients in Najran: prevalence is more among multi-centers visitors Saudi J Kidney Dis Transplant 14 2003 206 211
12. S.M. Alavian, B. Einollahi, and B. Hajarizadeh Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients Nephrology 8 2003 256 260
13. K.P. Souza, J.A. Luz, and S.A. Teles Hepatitis B and C in the hemodialysis unit of Tocantins, Brazil: serological and molecular profiles Mem Inst Oswaldo Cruz 98 2003 599 603
14. V. Djordjevic, K. Stojanovic, and M. Stojanovic Prevention of nosocomial transmission of hepatitis C infection in a hemodialysis unit: a prospective study Int J Artif Organs 23 2000 181 188
15. A.A. Hassan, and R. Khalili Hepatitis C in dialysis patients in Egypt: relationship to dialysis duration, blood transfusion, and liver disease [letter] Saudi J Kidney Dis Transplant 11 2000 72 75
16. A. Covic, L. Iancu, and C. Apetrei Hepatitis virus infection in haemodialysis patients from Moldavia Nephrol Dial Transplant 14 1999 40 45
17. F. Locatelli, D. Marcelli, and F. Conte Cardiovascular disease in chronic renal failure: the challenge continues. Registro Lombardo Dialisi e Trapianto Nephrol Dial Transplant 15 Suppl 5 2000 S69 S80
18. J.Y. Guh, Y.H. Lai, and C.Y. Yang Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients Nephron 69 1995 459 465
19. F. Fabrizi, P. Martin, and V. Dixit Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay Am J Kidney Dis 31 1998 647 654
20. F. Fabrizi, P. Martin, and V. Dixit Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis Aliment Pharmacol Ther 20 2004 1271 1277
21. C. Stehman Breen, S. Emerson, and D. Gretch Risk of death among chronic dialysis patients infected with hepatitis C virus Am J Kidney Dis 32 1998 629 634
22. E. Nakayama, T. Akiba, and F. Marumo Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy J Am Soc Nephrol 11 2000 1896 1902
23. M. Espinosa, A. Martin-Malo, and M. Alvarez de Lara Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients Nephrol Dial Transplant 16 2001 1669 1674
24. B.J.G. Pereira, S.N. Natov, and B.A. Bouthot Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group Kidney Int 53 1998 1374 1381
25. D.A. Goodkin, J.L. Bragg-Gresham, and K.G. Koenig Association of comorbid conditions and mortality in haemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcome and Practice Patterns Study (DOOPS) J Am Soc Nephrol 14 2003 3270 3277
26. Anonymous The current state of chronic dialysis treatment in Japan (as of December 31, 2000) Therap Apher Dial 7 2003 3 35
27. P. Maisonneuve, L. Agodoa, and R. Geller Cancer in patients on dialysis for end-stage renal disease: an international collaborative study Lancet 354 1999 93 99
28. M.E. Ellis, O. Alfurayh, and M.A. Halim Chronic non-A, non-B hepatitis complicated by end-stage renal failure treated with recombinant interferon alpha J Hepatol 18 1993 210 216
29. J.L. Fernandez, P. Rendo, and N. Del Pino Nephrologists' group for the study of HCV infection: a double-blind controlled trial of recombinant interferon-alpha2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels J Viral Hep 4 1999 113 119
30. P. Koenig, W. Vogel, and F. Umlauft Interferon treatment for chronic hepatitis C virus infection in uremic patients Kidney Int 45 1994 1507 1509
31. M. Raptopolou-Gigi, S. Spaia, and A. Garifallos Interferon-alpha2b treatment of chronic hepatitis C in haemodialysis patients Nephrol Dial Transplant 10 1995 1834 1837
32. S. Pol, V. Thiers, and F. Carnot Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients Kidney Int 47 1995 1412 1418
33. J. Izopet, L. Rostaing, and F. Moussion High rate of hepatitis C virus clearance in hemodialysis patients after interferon-therapy J Infect Dis 176 1997 1614 1617
34. A. Benci, M. Caremani, and D. Menchetti Low-dose leukocyte interferon-alpha therapy in dialysed patients with chronic hepatitis C Curr Med Res Opin 14 1998 141 144
35. T.M. Chan, P.C. Wu, and J.Y.N. Lau Interferon treatment for hepatitis C virus infection in patients on haemodialysis Nephrol Dial Transplant 12 1997 1414 1419
36. T. Tokumoto, K. Tanabe, and N. Ishikawa Effect of interferon-alfa treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C Transplant Proc 31 1999 2887 2889
37. M. Boran, and S. Cetin The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy Nephron 82 1999 22 26
38. S. Huraib, D. Tanimu, and S.A. Romeh Interferon-alpha in chronic hepatitis C infection in dialysis patients Am J Kidney Dis 34 1999 55 60
39. F. Degos, S. Pol, and M.L. Chaix The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study Nephrol Dial Transplant 16 2001 1017 1023
40. C. Hanrotel, O. Toupance, and S. Lavaud Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C Nephron 88 2001 120 126
41. D. Dincer, F. Besisik, and F. Oguz Genes of major histocompatibility complex class II influence chronic C hepatitis treatment with interferon in hemodialysis patients Int J Artif Organs 24 2001 212 214
42. I. Sporea, O. Golea, and C. Ursu Effect of alpha 2b interferon treatment in haemodialysis patients with chronic hepatitis C Rom J Gastroenterol 4 2001 285 288
43. M. Espinosa, M. Rodriguez, and A. Martin-Malo Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response Clin Nephrol 55 2001 220 226
44. M.W. Russo, C.D. Goldsweig, and I.M. Jacobson Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety Am J Gastroenterol 98 2003 1610 1615
45. F. Fabrizi, G. Dulai, and V. Dixit Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients Aliment Pharmacol Ther 18 2003 1071 1081
46. L. Rostaing, E. Chatelut, and J.L. Payen Pharmacokinetics of alfa IFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications J Am Soc Nephrol 9 1998 2344 2348
47. M. Uchihara, N. Izumi, and Y. Sakai Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon Nephron 80 1998 51 56
48. H. Izzedine, P. Lebon, and V. Launay-Vacher Tolerance and pharmacokinetics of high doses of interferon-alpha-2a in a haemodialysis patient [letter] Nephron 87 2001 91 92
49. M.S. Hirsch, N.E. Tolkoff-Rubin, and A.P. Kelly Pharmacokinetics of human and recombinant leukocyte interferon in patients with chronic renal failure who are undergoing hemodialysis [letter] J Infect Dis 148 1983 335
50. P. Martin, D. Carter, and F. Fabrizi Histopathological features of hepatitis C in renal transplant candidates Transplantation 69 2000 1479 1484
51. M. Lang, U. Neumann, and A. Kahl Combined liver and kidney transplantation: indications and long term follow-up Chirurg 72 2001 1154 1159
52. P. Kramer, F.W. Tenkate, and J. Jeekel Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients Lancet 1 1984 989 990
53. J. Kovarik, G. Mayer, and E. Pohanka Adverse effect of low-dose prophylactic human recombinant leukocyte interferon-alpha treatment in renal transplant recipients Transplantation 45 1988 402 405
54. E. Thervet, S. Pol, and C. Legendre Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients: a pilot study Transplantation 58 1994 625 628
55. Y. Harihara, Y. Kurooka, and T. Yanagisawa Interferon therapy in renal allograft recipients with chronic hepatitis C Transplant Proc 26 1994 2075
56. L. Rostaing, J. Izopet, and E. Baron Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients Transplantation 59 1995 1426 1431
57. O. Ozgur, S. Boyacioglu, and H. Telatar Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C Nephrol Dial Transplant 10 1995 2104 2106
58. M. Magnone, J.L. Holley, and R. Shapiro Interferon-alpha induced acute renal allograft rejection Transplantation 59 1995 1068 1070
59. L. Rostaing, A. Modesto, and E. Baron Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C Nephron 74 1996 512 516
60. Y. Ichikawa, M. Kyo, and T. Hanafusa A 20-year case study of a kidney transplant recipient with chronic active hepatitis C: clinical course and successful treatment for late acute rejection induced by interferon therapy Transplantation 65 1998 134 138
61. C.M. Toth, M. Pascual, and R.T. Chung Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation Transplantation 66 1998 1254 1258
62. T. Hanafusa, Y. Ichikawa, and H. Kishikawa Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years Transplantation 66 1998 471 476
63. G. Luciani, M. Bossola, and M. Muscaritoli Sustained response with negative serum HCV-mRMA and disappearance of antibodies after interferon-alpha therapy in a kidney transplant recipients with chronic active viral hepatitis C J Nephrol 16 2003 417 420
64. S. Tang, I.K. Chen, and V.K. Leung Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin J Hepatol 39 2003 875 879
65. K.H. Shu, J.L. Lan, and M.J. Wu Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients Transplantation 77 2004 1894 1896
66. T. Casanovas-Taltavull, C. Baliellas, and C. Benasco Efficacy and tolerance for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation Am J Gastroenterol 96 2001 1170 1177
67. J.M. Campistol, N. Esforzado, and J. Martinez Efficacy and tolerance of interferon-alfa(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients: pre- and post-renal transplantation assessment Nephrol Dial Transplant 14 1999 2704 2709
68. A. Rodrigues, T. Morgado, and J. Areias Limited benefits of IFN-α therapy in renal graft candidates with chronic viral hepatitis B or C Transplant Proc 29 1997 777 780
69. R. Duarte, S. Huraib, and R. Said Interferon-alfa facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis Am J Kidney Dis 25 1995 40 45
70. S. Huraib, A. Iqbal, and D. Tanimu Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic hepatitis C Am J Nephrol 21 2001 435 440
71. S. Bunnapradist, F. Fabrizi, and J. Vierling Hepatitis C therapy with long-term remission after renal transplantation Int J Artif Organs 25 2002 1189 1193
72. N. Kamar, O. Toupance, and M. Buchler Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation J Am Soc Nephrol 14 2003 2092 2098
73. 2b monotherapy Transplant Proc 35 2003 1745 1747
74. J.M. Cruzado, T. Casanovas-Taltavull, and J. Torras Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance Am J Transplant 3 2003 357 360
75. A. Bruchfeld, L. Stahle, and J. Andersson Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection: a pilot study J Viral Hepat 8 2001 287 292
76. A. Bruchfeld, L. Stahle, and J. Andersson Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C [letter] Nephrol Dial Transplant 16 2001 1729
77. A.C. Tan, J.T. Brouwer, and P. Glue Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study [letter] Nephrol Dial Transplant 16 2001 193 195
78. D.H. Mousa, A.H. Abdalla, and G. Al-Shoail Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C Transplant Proc 36 2004 1831 1834
79. M. Arambarri, M. Fernandez Lucas, and R. Echarri Therapy with interferon plus ribavirin in hemodialysis patient with PCR-positive viral hepatitis C Nefrologia 24 Suppl 3 2004 39 42
80. I. Suleymanlar, T. Sezer, and F. Isitan Efficacy of interferon alpha in acute hepatitis C in patients on chronic hemodialysis [letter] Nephron 79 1998 353 354
81. M. Gursoy, G. Gur, and H. Arslan Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment J Viral Hepat 8 2001 70 77
82. P. Urbanek, V. Tesar, and E. Prochazkova-Francisci Treatment of early diagnosed HCV infection in hemodialyzed patients with interferon-α: treatment of hepatitis C Blood Purif 22 2004 344 350
83. A.U. Neumann, N.P. Lam, and H. Dahari Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107
84. K.R. Reddy Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs Ann Pharmacother 34 2000 915 923
85. P. Martin, S. Mitra, and K. Farrington Pegylated (40kDa) interferon alfa-2a (Pegasys) is unaffected by renal impairment Hepatology 32 2000 370A
86. G. Barril, J.A. Quiroga, and P. Sanz Pegylated interferon-α2a kinetics during experimental haemodialysis: impact of permeability and pore size of dialyzers Aliment Pharmacol Ther 20 2004 37 44
87. I. Sporea, R. Sirli, and O. Golea Peg-interferon alfa 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis: preliminary results Rom J Gastroenterol 13 2004 99 102
88. A.E. Annichiarico, and M. Siciliano Pegylated interferon-alpha 2b monotherapy for hemodialysis patients with chronic hepatitis C [letter] Aliment Pharmacol Ther 20 2004 123 124
89. S. Mukherjee, R.K. Gilroy, and T.M. McCashland Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study Transplant Proc 35 2003 1478 1479
90. D. Marelli, J. Bresson, and H. Laks Hepatitis C-positive donors in heart transplantation Am J Transplant 2 2002 443 447
91. J.P. Ong, D.S. Barnes, and Z.M. Younossi Outcome of de novo hepatitis C virus infection in heart transplant recipients Hepatology 30 1999 1293 1298
92. E. File, M. Mehra, and S. Nair Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation Transplantation 76 2003 1096 1100
93. P.R. Pfau, R. Rho, and D. DeNofrio Hepatitis C transmission and infection by orthotopic heart transplantation J Heart Lung Transplant 19 2000 350 354
94. G.S. Gudmundsson, K. Maliniowska, and J.A. Robinson Five-year follow-up of hepatitis C positive heart transplant recipients who received hepatitis C-positive donor hearts Transplant Proc 35 2003 1536 1538
95. S.K. Haji, R.C. Starling, and R.K. Avery Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation J Heart Lung Transplant 23 2004 277 283
96. M. Castella, G. Tenderich, and M.M. Koerner Outcome of heart transplantation in patients previously infected with hepatitis C virus J Heart Lung Transplant 20 2001 595 598
97. K.D. Lake, C.I. Smith, and S.K.M. LaForest Policies regarding the transplantation of hepatitis C positive candidates and donor organs J Heart Lung Transplant 16 1997 917 921
98. A.D. Slater, B.J. Klein, and G. Sonnenfeld The effects of interferon alpha/beta in a model of rat heart transplantation J Heart Lung Transplant 11 1992 975 978
99. S. Fagiuoli, D.K. Cooper, and N. Zuhdi Hepatitis C status of heart transplant recipients Clin Transplant 12 1998 5 10
100. S. Fagiuoli, S. Pevere, and F. Minniti Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients Transplantation 75 2003 982 986